
ANI Pharmaceuticals ANIP
€ 69.77
2.41%
Quartalsbericht 2026-Q1
hinzugefügt 08.05.2026
ANI Pharmaceuticals Langfristiger Schuldenstrom 2011-2026 | ANIP
Langfristiger Schuldenstrom Jährlich ANI Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.92 M | 1.8 M | 1.56 M | 684 K | 850 K | 13.2 M | 9.94 M | 3.26 M | 3.35 M | - | - | - | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 13.2 M | 684 K | 4.07 M |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
103 K | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
102 K | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
181 K | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
3.5 M | - | - | $ 2.18 B | ||
|
Compugen Ltd.
CGEN
|
521 K | $ 2.1 | -5.41 % | $ 196 M | ||
|
Coherus BioSciences
CHRS
|
1.83 M | $ 1.45 | -7.94 % | $ 170 M | ||
|
AstraZeneca PLC
AZN
|
382 M | - | - | $ 96.9 B | ||
|
BioNTech SE
BNTX
|
45 M | $ 88.08 | -1.69 % | $ 21.3 B | ||
|
Athira Pharma
ATHA
|
465 K | - | - | $ 269 M | ||
|
CRISPR Therapeutics AG
CRSP
|
18.6 M | $ 51.84 | -8.97 % | $ 4.66 B | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
773 K | - | 0.74 % | $ 768 M | ||
|
Abcam plc
ABCM
|
8.5 M | - | - | $ 4.9 B | ||
|
Galera Therapeutics
GRTX
|
133 K | - | -32.59 % | $ 7.61 M | ||
|
Affimed N.V.
AFMD
|
539 K | - | -34.95 % | $ 21.5 M | ||
|
Celyad Oncology SA
CYAD
|
137 K | - | - | $ 12.5 M | ||
|
Berkeley Lights
BLI
|
3.29 M | - | -7.31 % | $ 87 M | ||
|
Celldex Therapeutics
CLDX
|
1.55 M | $ 28.62 | -4.38 % | $ 1.9 B | ||
|
Generation Bio Co.
GBIO
|
13 M | - | - | $ 344 M | ||
|
IMV
IMV
|
320 K | - | - | $ 13.1 M | ||
|
Akouos
AKUS
|
671 K | - | 0.23 % | $ 488 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
235 K | $ 0.71 | -10.18 % | $ 32.4 M | ||
|
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | ||
|
Esperion Therapeutics
ESPR
|
2.1 M | $ 3.13 | - | $ 651 M | ||
|
Eton Pharmaceuticals
ETON
|
65 K | $ 29.13 | 0.8 % | $ 784 M | ||
|
Forte Biosciences
FBRX
|
416 K | $ 16.52 | -1.02 % | $ 214 M | ||
|
Freeline Therapeutics Holdings plc
FRLN
|
2.66 M | - | - | $ 384 M | ||
|
Gracell Biotechnologies
GRCL
|
17.5 M | - | - | $ 3.37 B | ||
|
Anika Therapeutics
ANIK
|
2.05 M | $ 14.48 | -2.1 % | $ 208 M | ||
|
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
215 K | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
554 K | - | 1.93 % | $ 17.4 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
56 K | $ 3.09 | -2.22 % | $ 5.09 M | ||
|
Aptose Biosciences
APTO
|
193 K | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
337 K | - | -39.0 % | $ 4.57 M | ||
|
Albireo Pharma
ALBO
|
1.4 M | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
316 K | - | 4.14 % | $ 49.1 M |